Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma: The PERM Study

Trial Profile

Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma: The PERM Study

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms PERM
  • Most Recent Events

    • 07 Jan 2016 Planned End Date changed from 1 Oct 2019 to 1 Feb 2020, as reported by ClinicalTrials.gov.
    • 07 Jan 2016 Planned primary completion date changed from 1 Oct 2019 to 1 Feb 2020, as reported by ClinicalTrials.gov.
    • 07 Jan 2016 Planned initiation date changed from 1 Oct 2015 to 1 Feb 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top